Pharmacogenetic vs. Concentration-controlled optimization of tacrolimus dosing in renal allograft recipients

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 595-596

  Kuypers, D R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYTOCHROME P450 3A5; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ALLELE; DELAYED GRAFT FUNCTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG TARGETING; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; LETTER; LOADING DRUG DOSE; NEPHROTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; TREATMENT OUTCOME; ALLOTRANSPLANTATION; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PHENOTYPE;

CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHARMACOGENETICS; PHENOTYPE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77958481477     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.129     Document Type: Letter

References (3)

1. Thervet, E. et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721-726 (2010).
2. Kuypers, D. et al. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin-inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug. Monit. (2010), e-pub ahead of print 3 June 2010.
3. Kuypers, D.R., de Jonge, H., Naesens, M., Lerut, E., Verbeke, K. & Vanrenterghem, Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82, 711-725 (2007).